Table of Contents - WOC 2012

WOC2012 Abstract Book
IS-COR-SA 182 (6)
Conjunctival Recession and Resection for the Management of
Moorn›s Ulcer
Al-Swailem Samar
Obtaining a wet, non-inflamed and intact corneal and conjunctival epithelium
are important steps toward achieving healthy ocular surface. A range of
proposed surgical techniques, safety, efficacy levels, limitations, complications,
and personal experiences with using amniotic membrane transplantation in the
treatment of Moorn›s ulcer will be addressed.
IS-COR-SA 182 (7)
Case Presentation and Panel Discussion
Al Muammar Abdulrahman (1)
1. King Saud University
During this presentation, variety of interesting and challenging conjunctival
diseases will be presented using history and clinical photography. All of our
panelists will share their thoughts regarding the diagnosis and appropriate
management then we will present what was done for the patients including
post treatment clinical photography.
Vascular Occlusion: New Treatments and Regimens, Including
Surgery
Sat 18 Feb 10:30 - 12:00 Hall 2
IS-RET-SA 183 (1)
Natural History of CRVO/BRVO
Soubrane Gisèle (1)
1. University Paris East
The VA at presentation is larger in ischemic than with nonischemic CRVO.
Visual outcome is generally poor in CRVO. Eyes with BRVO usually have at
presentation, vision worse than 20/40 and mostly improve (but rarely beyond
20/40). Ischemic CRVO portend a risk of neovascularisation which is relatively
low in BRVO. Macular edema is common but resolves in about 30% for
nonischemic CRVO.Conversely, chronic macular edema is associated with
poor visual prognosis. In BRVO, macular edema may develop in 10% of eyes
and resolve in nearly half of the eyes.
IS-RET-SA 183 (2)
Anti-VEFG Therapy for CRVO/BRVO
Bandello Francesco (1)
1.
Raffaele
BRVO and CRVO can determine a severe visual impairment. Several studies
have shown elevated intravitreal VEGF levels after BRVO and CRVO. Some
randomized clinical trials have recently demonstrated beneficial effects
of anti-VEGF approach in BRVO and CRVO management. In particular,
intravitreal anti-VEGF can improve both visual acuity and macular edema in a
considerable portion of patients. Further studies are warranted to ascertain the
best treatment timing and the most appropriate therapeutic regimen.
190
IS-RET-SA 183 (3)
Posterior Sub-Tenon Triamcinolone Injection for Chronic Macular
Oedema Associated With Retinal Vein Occlusion
Wolfensberger Thomas (1)
1. Jules Gonin University Eye Hospital
Purpose: To evaluate the effectiveness and safety of posterior sub-Tenon
(PST) triamcinolone (TA) injection for persistent macular edema associated
with central (CRVO) or branch retinal vein occlusion (BRVO).
Design: Retrospective, non-comparative interventional case series.
Participants: Seven-teen consecutive eyes of 17 patients characterized by
macular edema lasting more than 3 months and with a visual acuity of less
than 20/40 were enrolled between June 2005 and December 2006. Eight eyes
presented with BRVO, 9 eyes with CRVO.
Intervention: PST injection of 40 mg TA was performed in topical anaesthesia.
All patients were followed for at least 6 months.
Main Outcome Measures: Visual and anatomic responses were evaluated
before injection, and at 1, 3, 6, and 12 (if required) months after the injections.
Results: In the BRVO group, mean foveal thickness was 555.6 ± 33.0 µm
preoperatively, and 389.5 ± 49.3 µm and 262.3 ± 57.6 µm at 1 and 12 month
follow-up, respectively. Statistical analysis showed significant differences
between preoperative and postoperative measurements (P < .05, at 1, 12
months, paired t test). Improvement of visual acuity by at least 0.2 logMAR was
seen in 6 (75%) of the 8 eyes. Intraocular pressure (IOP) elevation of 22 mmHg
or higher was found in 2 (20%) of 8 eyes. Cataract progression was noted in
2 (25%) of 8 phakic eyes. In the CRVO group, mean foveal thickness was
559.7 ± 34.6 µm preoperatively, and 283.6 ± 40.1 µm and 258.2 ± 41.6 µm at
1 and 12 month follow-up, respectively. Statistical analysis showed significant
differences between preoperative and postoperative measurements (P < .01,
at 1, 12 months, paired t test). Improvement of visual acuity by at least 0.2
logMAR was seen in 7 (78%) of the 9 eyes. Intraocular pressure elevation of
22 mmHg or higher was found in 3 (33%) of 9 eyes. Cataract progression was
noted in 5 (56%) of 9 phakic eyes.
Conclusions: PST injection of TA appears to be an effective treatment for
chronic macular edema associated with BRVO or CRVO.
IS-RET-SA 183 (4)
Dexamethasone (Ozurdex) for CRVO/BRVO
Loewenstein Anat
(1)
1. Tel Aviv Medical Center and Sackler Faculty of Medicine, Tel Aviv University
Ozurdex (Allergan) intravitreal implant is the first treatment being approved by
FDA and EMA to treat macular edema in patients with retinal vein occlusion.
It was developed to grant a slow release of dexamethasone at the posterior
segment of the eye for up to 6 months and can be injected in an outpatient
setting. We overview the recent clinical trials and assess the accruing
clinical experience with Ozurdex treatment from the perspective of practicing
ophthalmologists.
IS-RET-SA 183 (5)
Vitrectomy for Macular Edema Due to CRVO
Le Mer Yannick (1)
1. Fondation Ophtalmologique A. de Rothschild
Vitrectomy could be efficient in improving macular edema in several ways:
• “Decompression” of a macular edema by peeling of the internal limiting
membrane
• “Decompression” of the central retina vein by opening of the scleral ring
• Retinal reperfusion by a fibrinolytic agent injection in the occluded vein
• Improving of the retina oxygenation by removing the vitreous gel
Nevertheless, the lack of large scale comparative studies make the surgical
indications still controversial. The new medical treatments will probably close
the debate.